You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for HIOC
HIOC is a selective TrkB receptor agonist. Protects neurons from excitotoxicity. Protects retinas from light-induced retinal degeneration (LIRD) in vivo. Blood brain barrier and blood-retinal barrier penetrant.
Technical Data for HIOC
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for HIOC
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for HIOC
The following data is based on the product molecular weight 301.34. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.32 mL||16.59 mL||33.19 mL|
|5 mM||0.66 mL||3.32 mL||6.64 mL|
|10 mM||0.33 mL||1.66 mL||3.32 mL|
|50 mM||0.07 mL||0.33 mL||0.66 mL|
References for HIOC
References are publications that support the biological activity of the product.
Setterholm et al (2015) Gram-scale, chemoselective synthesis of N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC) Tetrahedron Lett. 56 3413 PMID: 26028783
Shen et al (2012) N-acetyl serotonin derivatives as potent neuroprotectants for retinas Proc.Natl.Acad.Sci.USA 109 3540 PMID: 22331903
If you know of a relevant reference for HIOC, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: HIOC, HIOC supplier, Selective, TrkB, receptor, agonists, agonism, excitotoxicity, retinal, degeneration, blood, brain, barrier, BBB, neuroprotectant, Trk, Receptors, 5961, Tocris Bioscience
Citations for HIOC
Citations are publications that use Tocris products.
Currently there are no citations for HIOC. Do you know of a great paper that uses HIOC from Tocris? Please let us know.
Reviews for HIOC
There are currently no reviews for this product. Be the first to review HIOC and earn rewards!
Have you used HIOC?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease PosterUpdated
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.